[go: up one dir, main page]

AR067538A1 - Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa - Google Patents

Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa

Info

Publication number
AR067538A1
AR067538A1 ARP080103024A ARP080103024A AR067538A1 AR 067538 A1 AR067538 A1 AR 067538A1 AR P080103024 A ARP080103024 A AR P080103024A AR P080103024 A ARP080103024 A AR P080103024A AR 067538 A1 AR067538 A1 AR 067538A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
noh
atom
links
hydrogen
Prior art date
Application number
ARP080103024A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR067538A1 publication Critical patent/AR067538A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1): la que: R1 es hidrogeno o alquilo inferior; R2 es alquilo inferior, -(CH2)n-cicloalquilo, -(CH2)n-hetero- cicloalquilo, -(CH2)n-arilo, -(CH2)n-heteroarilo, -(CH2)nOH, -(CH2)nCH(CH3)OH o -(CH2)nOCH3: o R1 y R2, junto con el átomo de N al que están unidos forman un anillo monocíclico de 5 a 7 eslabones, que contiene el átomo de N, al que R1 y R2 están unidos, y opcionalmente otro heteroátomo elegido entre O y S, dicho anillo monocíclico de 5 a 7 eslabones está sin sustituir o mono- o di-sustituido por sustituyentes elegidos con independencia entre hidroxi, alquilo inferior y -(CH2)nOH; R3 es uno o más sustituyentes elegidos con independencia entre H, halogeno, alquilo inferior y alcoxi inferior; R4 es hidrogeno, -OH, -NHC(=O)CH3 o -NHS(=O) (=O)CH3;n es el numero 1, 2, 3 o 4; y las sales farmacéuticamente aceptables del mismo. Estos compuestos y las composiciones farmacéuticas que los contienen son utiles para el tratamiento de enfermedades, por ejemplo la diabetes metillas de tipo II y el síndrome metabolico.
ARP080103024A 2007-07-17 2008-07-14 Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa AR067538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95016807P 2007-07-17 2007-07-17

Publications (1)

Publication Number Publication Date
AR067538A1 true AR067538A1 (es) 2009-10-14

Family

ID=40019292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103024A AR067538A1 (es) 2007-07-17 2008-07-14 Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa

Country Status (16)

Country Link
US (1) US7790711B2 (es)
EP (1) EP2178845B1 (es)
JP (1) JP5189165B2 (es)
KR (1) KR101158191B1 (es)
CN (1) CN101743226B (es)
AR (1) AR067538A1 (es)
AU (1) AU2008277783B2 (es)
BR (1) BRPI0814825A2 (es)
CA (1) CA2693457C (es)
CL (1) CL2008002052A1 (es)
ES (1) ES2423181T3 (es)
PE (1) PE20090813A1 (es)
RU (1) RU2440989C2 (es)
TW (1) TWI372623B (es)
WO (1) WO2009010416A2 (es)
ZA (1) ZA201000318B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276280B2 (ja) 2005-11-21 2009-06-10 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
RU2455285C2 (ru) 2007-05-18 2012-07-10 Сионоги Энд Ко., Лтд. АЗОТСОДЕРЖАЩЕЕ ГЕТЕРОЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
CA2713409A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103209957A (zh) * 2010-08-09 2013-07-17 盐野义制药株式会社 氨基金刚烷氨基甲酸酯衍生物的制备方法
CA2836728C (en) * 2011-06-10 2016-08-16 Sk Biopharmaceuticals Co., Ltd. 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2797416B1 (en) 2011-12-28 2017-08-09 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9044017B2 (en) 2013-10-17 2015-06-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015058020A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
KR20160072154A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
KR20170039121A (ko) 2014-07-31 2017-04-10 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
BR112017004613A2 (pt) 2014-09-12 2017-12-05 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
KR101759874B1 (ko) * 2015-08-07 2017-07-21 코스맥스 주식회사 11β-hydroxysteroid dehydrogenase type 1의 활성을 저해하는 화합물을 포함하는 화장료 조성물 또는 피부 외용제 조성물
US10324166B2 (en) * 2015-09-28 2019-06-18 Rockwell Collins, Inc. Affordable combined pulsed/FMCW radar AESA
BR112018011272A2 (pt) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
EP3258288B1 (en) * 2016-06-14 2024-07-31 Rohde & Schwarz GmbH & Co. KG Method for testing the transmission and reflection properties of an automotive radome body as well as apparatus for testing the transmission and reflection properties of an automotive radome body
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US10233155B2 (en) 2016-12-29 2019-03-19 Dow Agrosciences Llc Processes for the preparation of pesticide compounds
EP3562807B1 (en) 2016-12-29 2022-08-03 Corteva Agriscience LLC Processes for the preparation of pesticidal compounds
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
WO1998041519A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
ATE482200T1 (de) 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
CA2534221A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050245532A1 (en) * 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050245533A1 (en) * 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
US20050245534A1 (en) * 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
CA2565843A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
CA2565632C (en) 2004-05-07 2013-04-23 Janssen Pharmaceutica N.V. Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006017542A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
MY146435A (en) 2004-08-30 2012-08-15 Janssen Pharmaceutica Nv N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
CN101039908B (zh) 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
PL1807072T3 (pl) 2004-10-29 2009-06-30 Lilly Co Eli Cykloalkilowe pochodne laktamów jako inhibitory 11-ß-HSD1
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
US20060148871A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Metabolic stabilization of substituted adamantane
CA2594116A1 (en) * 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
MX2007008238A (es) 2005-01-05 2007-08-17 Abbott Lab Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
JPWO2006104280A1 (ja) 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
EP1866391B1 (en) 2005-03-31 2019-05-22 Badger Licensing LLC Multiphase production of ethylbenzene or cumene
JP4880671B2 (ja) * 2005-04-05 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー １Ｈ−ピラゾール４−カルボキシルアミドその製造方法および１１β−ヒドロキシステロイドデヒドロゲナーゼとしてのその使用
EP1894919B1 (en) * 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
JP4276280B2 (ja) * 2005-11-21 2009-06-10 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
PL1999114T3 (pl) * 2006-03-22 2015-12-31 Hoffmann La Roche Pirazole jako 11-Beta-HSD-1
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF

Also Published As

Publication number Publication date
TW200913992A (en) 2009-04-01
KR20100034763A (ko) 2010-04-01
AU2008277783A1 (en) 2009-01-22
CA2693457C (en) 2012-10-23
JP2010533670A (ja) 2010-10-28
US20090023709A1 (en) 2009-01-22
CN101743226B (zh) 2012-10-10
CN101743226A (zh) 2010-06-16
TWI372623B (en) 2012-09-21
US7790711B2 (en) 2010-09-07
KR101158191B1 (ko) 2012-06-19
EP2178845A2 (en) 2010-04-28
WO2009010416A3 (en) 2009-03-05
RU2440989C2 (ru) 2012-01-27
ZA201000318B (en) 2010-10-27
EP2178845B1 (en) 2013-06-19
WO2009010416A2 (en) 2009-01-22
PE20090813A1 (es) 2009-06-27
RU2010105299A (ru) 2011-08-27
BRPI0814825A2 (pt) 2015-02-03
ES2423181T3 (es) 2013-09-18
AU2008277783B2 (en) 2012-09-20
CA2693457A1 (en) 2009-01-22
CL2008002052A1 (es) 2009-05-22
JP5189165B2 (ja) 2013-04-24

Similar Documents

Publication Publication Date Title
AR067538A1 (es) Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
MX2020000261A (es) Nuevos compuestos.
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
ES2694053T3 (es) Compuestos novedosos como inhibidores de histona desacetilasa 6 y composiciones farmacéuticas que comprenden los mismos
AR064736A1 (es) Agonistas de gpcr
AR029740A1 (es) Compuestos derivados de la n-(4-carbamimidoil-fenil)-glicina ,su uso , procedimiento de obtencion de los mismos, preparados farmaceuticos que los contienen y compuestos derivados de la n-(4-ciano-fenil)-glicina
PE20091425A1 (es) Derivados de aminotiazol
AR061644A1 (es) Derivados de benzofurano
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
ES2668775T3 (es) Compuestos tetracíclicos
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
PE20090987A1 (es) Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR060401A1 (es) Derivados de cromen-2-ona
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
AR078606A1 (es) Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal